ArticleScientific reports2025
KIN17 modulates the WNT/β-catenin pathway and epithelial mesenchymal transition in non-small cell lung cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
KIN17 may impact epithelial mesenchymal transition (EMT) of cancer cells. However, whether KIN17 impacts EMT in non-small cell lung cancer (NSCLC) remains unknown, which was explored in this study. Bioinformatics analyses were conducted to investigate KIN17's expression pattern, prognostic value in patients of NSCLC and its related genes. The expression of KIN17 was down-regulated in H1299 NSCLC cells and the invasion, proliferation, and migration upon KIN17 knockdown was examined. In addition, the expression of marker proteins of EMT and the Wingless/int1 (WNT1) signaling pathway upon KIN17 knockdown were examined in vitro and in vivo. mRNA and/or protein expression of KIN17 was higher in multiple cancer tissues, especially in NSCLC tissues. Patients of NSCLC with increased KIN17 expression had lowest disease free survival (DFS). The co-expression network of KIN17 enriched pathways revealed links to tumorigenesis and development. KIN17 knockdown in H1299 cells greatly decreased cell invasion, proliferation, and migration. In addition, KIN17 knockdown increased expression of E-cadherin and reduced expression of Vimentin and N-cadherin, which are all markers of EMT. Moreover, KIN17 knockdown in H1299 cells down-regulated the WNT signaling pathway, an inducer of EMT, as evidenced by reduced expression of WNT1 and β-catenin proteins. Finally, KIN17 knockdown significantly reduced tumor growth and down-regulated EMT and the expression of WNT1 and β-catenin proteins in NSCLC xenograft mice. Collectively, KIN17 knockdown suppressed the progression of NSCLC, potentially involving down-regulation of EMT and the WNT/β-catenin pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.